St. Jude Medical (St. Paul, Minnesota) took another hit for its Riata line of electrophysiology leads via an FDA announcement that all patients with these leads should be evaluated for lead externalization. The news dropped the firm's shares at the New York Stock Exchange, falling to as low as $36.59 from the day-high of $38. Recent reports had already driven down share prices with reports in July stating that a weak earnings environment is in the firm's future. Read More
